Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SNT-3012
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Champalimaud Foundation
Deal Size : Undisclosed
Deal Type : Collaboration
Sonata and Champalimaud Foundation Announce Collaboration for SNT-3012
Details : The collaboration aims to focus on the clinical development of SNT-3012. Currently being evaluated in the preclinical trial studies for the treatment of pancreatic cancer and colorectal cancers.
Product Name : SNT-3012
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 03, 2024
Lead Product(s) : SNT-3012
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Champalimaud Foundation
Deal Size : Undisclosed
Deal Type : Collaboration